ResMed (RMD) 10-Q 28 Oct 16 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2016	Oct. 20, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	rmd
Entity Registrant Name	RESMED INC
Entity Central Index Key	943,819
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		140,965,500

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 781,658	$ 731,434
Accounts receivable, net of allowance for doubtful accounts of $11,293 and $12,555 at September 30, 2016 and June 30, 2016, respectively	347,137	382,086
Inventories (note 3)	253,828	224,456
Prepaid expenses and other current assets	92,229	81,743
Total current assets	1,474,852	1,419,719
Non-current assets:
Property, plant and equipment, net (note 4)	390,797	384,276
Goodwill (note 6)	1,062,758	1,059,245
Other intangible assets, net (note 7)	289,673	299,808
Deferred income taxes	62,926	55,496
Other assets	41,258	38,161
Total non-current assets	1,847,412	1,836,986
Total assets	3,322,264	3,256,705
Current liabilities:
Accounts payable	80,489	92,571
Accrued expenses	153,969	156,805
Deferred revenue	47,665	50,009
Income taxes payable	38,807	39,166
Short-term debt (note 9)	299,625	299,438
Total current liabilities	620,555	637,989
Non-current liabilities:
Deferred revenue	45,736	40,281
Deferred income taxes	8,920	9,061
Other long-term liabilities	974	1,211
Long-term debt (note 9)	873,511	873,332
Total non-current liabilities	929,141	923,885
Total liabilities	1,549,696	1,561,874
Commitments and contingencies (note 13)
Stockholders' equity: (note 11)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 181,974,343 issued and 140,888,109 outstanding at September 30, 2016 and 181,747,157 issued and 140,660,923 outstanding at June 30, 2016	564	563
Additional paid-in capital	1,321,522	1,303,238
Retained earnings	2,190,028	2,160,299
Treasury stock, at cost, 41,086,234 shares at September 30, 2016, and June 30, 2016	(1,546,611)	(1,546,611)
Accumulated other comprehensive loss	(192,935)	(222,658)
Total stockholders' equity	1,772,568	1,694,831
Total liabilities and stockholders' equity	$ 3,322,264	$ 3,256,705

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 11,293	$ 12,555
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.004	$ 0.004
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	181,974,343	181,747,157
Common stock, shares outstanding	140,888,109	140,660,923
Treasury stock, shares held	41,086,234	41,086,234

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements Of Income [Abstract]
Net revenue	$ 465,450	$ 411,647
Cost of sales (excluding amortization of acquired intangible assets)	196,266	173,028
Gross profit	269,184	238,619
Operating expenses:
Selling, general and administrative	128,851	111,095
Research and development	34,446	27,192
Amortization of acquired intangible assets	11,741	2,307
Total operating expenses	175,038	140,594
Income from operations	94,146	98,025
Other (loss) income, net:
Interest (expense) income, net	(2,493)	3,422
Other, net	1,272	(2,003)
Total other (loss) income, net	(1,221)	1,419
Income before income taxes	92,925	99,444
Income taxes	16,818	16,527
Net income	$ 76,107	$ 82,917
Basic earnings per share	$ 0.54	$ 0.59
Diluted earnings per share (note 2)	0.54	0.58
Dividend declared per share	$ 0.33	$ 0.30
Basic shares outstanding (000's)	140,785	140,309
Diluted shares outstanding (000's)	142,090	142,280

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 76,107	$ 82,917
Other comprehensive income (loss):
Foreign currency translation gain (loss) adjustments	29,723	(122,108)
Comprehensive income (loss)	$ 105,830	$ (39,191)

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net income	$ 76,107	$ 82,917
Depreciation and amortization	27,775	18,403
Stock-based compensation costs	12,049	12,383
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	36,207	30,498
Inventories	(28,073)	(17,194)
Prepaid expenses, net deferred income taxes and other current assets	(19,115)	(3,526)
Accounts payable, accrued expenses and other liabilities	(18,707)	1,127
Net cash provided by operating activities	86,243	124,608
Cash flows from investing activities:
Purchases of property, plant and equipment	(14,560)	(16,403)
Patent registration costs	(2,471)	(2,423)
Business acquisitions, net of cash acquired	(3,090)
Investments in cost-method investments	(2,758)	(4,582)
Proceeds (Payments) on maturity of foreign currency contracts	9,710	(39,341)
Net cash used in investing activities	(13,169)	(62,749)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	6,330	4,352
Purchases of treasury stock		(57,857)
Proceeds from borrowings, net of borrowing costs	25,000	200,000
Repayment of borrowings	(25,000)	(8)
Dividends paid	(46,378)	(42,079)
Net cash (used in) from financing activities	(40,048)	104,408
Effect of exchange rate changes on cash	17,198	(61,463)
Net increase in cash and cash equivalents	50,224	104,804
Cash and cash equivalents at beginning of period	731,434	717,249
Cash and cash equivalents at end of period	781,658	822,053
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	28,261	18,118
Interest paid	6,401	1,247
Fair value of assets acquired, excluding cash	1,891
Goodwill on acquisition	457
Deferred payments	742
Total cash component of purchase price	$ 3,090

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	(1) Summary of Significant Accounting Policies  Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2017.  The condensed consolidated financial statements for the three months ended September 30, 2016 and 2015 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2016.  New Accounting Pronouncements  In May, 2014, the FASB issued Accounting Standards Update (ASU), ASU No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact on our financial condition, results of operations and cash flows as a result of the adoption of ASU 2014-09, however, we do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard was effective for us beginning in the first quarter of fiscal 2017. As a result of the adoption, we reclassified debt issuance costs of $0.6 million and $1.7 million, from other assets to short-term debt and long-term debt, respectively, in our consolidated balance sheet as of June 30, 2016. The adoption of this guidance did not impact our consolidated statements of earnings, comprehensive income, s tock holders’ equity, or cash flows.  In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In February 2016, the FASB issued ASU No. 2016-02, “Leases”. Under the new guidance, lessees are required to recognize lease assets and liabilities on the balance sheet for leases classified as operating leases under current GAAP. This ASU is effective for the company beginning July 1, 2019. We are currently evaluating the impact of this standard on our consolidated financial statements.  In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, which requires companies to recognize additional tax benefits or expenses related to the vesting or settlement of employee share-based awards (the difference between the actual benefit for tax purposes and the tax benefit initially recognized for financial reporting purposes) as income tax benefit or expense in earnings, rather than in additional paid-in capital, in the reporting period in which they occur. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The new standard is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. We elected to early adopt this ASU during the fourth quarter of fiscal year 2016 and are therefore required to report the impacts as though the ASU had been adopted on July 1, 2015. Accordingly, we recognized a reduction in income tax expense and an increase in operating cash flows related to the vesting or settlement of employee share-based awards of $2.5 million in each of the three month periods ended September 30, 201 6 and September 30, 201 5 .

Earnings Per Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	(2) Earnings Per Share  Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.  Stock options and restricted stock units of 264,672 and 98,697 , for the three months ended September 30, 2016 and 2015, respectively, were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive.  Basic and diluted earnings per share for the three months ended September 30, 2016 and 2015 are calculated as follows (in thousands except per share data):    Three Months Ended September 30,  2016 2015  Numerator:  Net Income $ 76,107 $ 82,917  Denominator:  Basic weighted-average common shares outstanding 140,785 140,309  Effect of dilutive securities:  Stock options and restricted stock units 1,305 1,971  Diluted weighted average shares 142,090 142,280  Basic earnings per share $ 0.54 $ 0.59  Diluted earnings per share $ 0.54 $ 0.58 

Inventories

Inventories	3 Months Ended
	Sep. 30, 2016
Inventories [Abstract]
Inventories	(3) Inventories  Inventories were comprised of the following at September 30, 2016 and June 30, 2016 (in thousands):   September 30, 2016 June 30, 2016  Raw materials $ 65,416 $ 67,121  Work in progress 4,859 3,939  Finished goods 183,553 153,396  Total inventories $ 253,828 $ 224,456 

Property, Plant And Equipment

Property, Plant And Equipment	3 Months Ended
	Sep. 30, 2016
Property, Plant And Equipment [Abstract]
Property, Plant And Equipment	(4) Property, Plant and Equipment  Property, plant and equipment were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):    September 30, 2016 June 30, 2016  Machinery and equipment $ 197,075 $ 197,485  Computer equipment 163,787 154,105  Furniture and fixtures 44,363 40,776  Vehicles 7,477 9,060  Clinical, demonstration and rental equipment 83,152 79,641  Leasehold improvements 34,126 33,795  Land 55,194 54,338  Buildings 233,047 229,502  818,221 798,702  Accumulated depreciation and amortization (427,424) (414,426)  Property, plant and equipment, net $ 390,797 $ 384,276 

Cost-Method Investments

Cost-Method Investments	3 Months Ended
	Sep. 30, 2016
Cost-Method Investments [Abstract]
Cost-Method Investments	 (5) Cost-Method Investments  The aggregate carrying amount of our cost-method investments at September 30, 2016 and June 30, 2016, was $36.6 million and $ 33.8 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.  We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows. We have determined that the fair value of our cost-method investments exceed their carrying values.  The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2016 and 2015 (in thousands):    Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ 33,815 $ 25,600  Investments 2,758 4,582  Balance at the end of the period $ 36,573 $ 30,182 

Goodwill

Goodwill	3 Months Ended
	Sep. 30, 2016
Goodwill And Other Intangible Asset [Abstract]
Goodwill	(6) Goodwill Changes in the carrying amount of goodwill for the three months ended September 30, 2016, and 2015 were as follows (in thousands):    Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ 1,059,245 $ 264,261  Other adjustments, net 457 -  Foreign currency translation adjustments 3,056 (1,443)  Balance at the end of the period $ 1,062,758 $ 262,818 .

Other Intangible Assets

Other Intangible Assets	3 Months Ended
	Sep. 30, 2016
Goodwill And Other Intangible Asset [Abstract]
Other Intangible Assets	(7) Other Intangible Assets Other intangible assets were comprised of the following as of September 30, 2016 and June 30, 2016 (in thousands):    September 30, 2016 June 30, 2016  Developed/core product technology $ 203,041 $ 202,050  Accumulated amortization (72,493) (63,825)  Developed/core product technology, net 130,548 138,225  Trade names 48,624 47,897  Accumulated amortization (5,733) (3,832)  Trade names, net 42,891 44,065  Non-compete agreements 3,133 3,089  Accumulated amortization (2,013) (1,899)  Non compete agreements, net 1,120 1,190  Customer relationships 119,293 118,528  Accumulated amortization (29,905) (26,783)  Customer relationships, net 89,388 91,745  In-process research and development 4,100 4,100  Accumulated amortization - -  In-process research and development, net 4,100 4,100  Patents 78,388 74,034  Accumulated amortization (56,762) (53,551)  Patents, net 21,626 20,483  Total other intangibles, net $ 289,673 $ 299,808  Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two and fifteen years. There are no expected residual values related to these intangible assets. In-process research and development is amortized over the estimated useful life of the assets, once the research and development efforts are completed. At least on an annual basis, we evaluate the in-process research and development balances for impairment.

Product Warranties

Product Warranties	3 Months Ended
	Sep. 30, 2016
Product Warranties [Abstract]
Product Warranties	(8) Product Warranties  Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the three months ended September 30, 2016 and 2015 are as follows (in thousands):    Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ 15,043 $ 9,823  Warranty accruals for the period 5,243 1,790  Warranty costs incurred for the period (2,855) (2,039)  Foreign currency translation adjustments 147 (691)  Balance at the end of the period $ 17,578 $ 8,883 

Debt

Debt	3 Months Ended
	Sep. 30, 2016
Debt [Abstract]
Debt	 (9) Debt Debt at September 30, 2016 and June 30, 2016 consisted of the following (in thousands):   September 30, 2016 June 30, 2016  Short-term debt $ 300,000 $ 300,000  Deferred borrowing costs (375) (562)  Short-term debt, net 299,625 299,438   Long-term debt 875,000 875,000  Deferred borrowing costs (1,489) (1,668)  Long-term debt, net 873,511 873,332  Total debt $ 1,173,136 $ 1,172,770  Credit Facility  On October 31, 2013, we entered into a revolving credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger , providing for a revolving credit facility of $700 million, with an uncommitted option to increase the revolving credit facility by an additional $300 million. On April 4, 2016, in connection with our acquisition of Brightree LLC (“Brightree”), we entered into a first amendment to the revolving credit agreement to increase the size of the revolving credit facility from $700 million to $1 billion, with an uncommitted option to increase the revolving credit facility by an additional $300 million, and to make other modifications to provide for the acquisition of Brightree. The credit facility terminates on October 31, 2018 , when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2016, the interest rate that was being charged on the outstanding principal amount was 2.0% . A commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility. The credit facility also includes a $25 million sublimit for letters of credit.  Our obligations under the revolving credit agreement are unsecured but are guaranteed by certain of our direct and indirect U. S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio.  At September 30, 2016, there was $875.0 million outstanding under the revolving credit facility.  Term Loan  On April 4, 2016, in connection with the Brightree acquisition, we also entered into a credit agreement (the “term loan credit agreement”) providing a $300 million senior unsecured one -year term loan credit facility.  Our obligations under the term loan credit agreement are unsecured but are guaranteed by certain of our direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The term loan credit facility terminates on April 3, 2017 , when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the term loan credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2016, the interest rate that was being charged on the outstanding principal amount was 2.0% . The term loan credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of funded debt to EBITDA (as defined in the term loan credit agreement) and an interest coverage ratio.  The proceeds from the funding of the term loan credit facility were used to pay a portion of the acquisition consideration for the Brightree acquisition, as well as to pay fees and expenses in connection with the acquisition, the amendment to the revolving credit agreement and the term loan credit agreement.  At September 30, 2016, there was $300.0 million outstanding under the term loan credit agreement.

Stock-Based Employee Compensati

Stock-Based Employee Compensation	3 Months Ended
	Sep. 30, 2016
Stock-Based Employee Compensation [Abstract]
Stock-Based Employee Compensation	(10) Stock-Based Employee Compensation  We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest. We estimate the fair value stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:    Three Months Ended September 30,  2016 2015  Stock options:  Weighted average grant date fair value $ - $ -  Weighted average risk-free interest rate - -  Expected option life in years - -  Dividend yield - -  Expected volatility - -   ESPP purchase rights:  Weighted average grant date fair value $ 11.88 $ 14.22  Weighted average risk-free interest rate 0.4% 0.1%  Expected option life in years 6 months 6 months  Dividend yield 2.14% 1.73%  Expected volatility 23% 26% 

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2016
Stockholders' Equity [Abstract]
Stockholders' Equity	(11) Stockholders’ Equity  Common Stock. Since the inception of our share repurchase programs and through September 30, 2016, we have repurchased a total of 41.1 million shares at a cost of $1.5 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. We have temporarily suspended our share repurchase program due to recent acquisitions. Accordingly, we did no t repurchase any shares during the three months ended September 30, 2016. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors . At September 30, 2016, 13.6 million additional shares can be repurchased under the approved share repurchase program.  Preferred Stock. In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2016 and June 30, 2016 .  Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”). The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.  The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2016 is 12.1 million . The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted).  At September 30, 2016, there were $ 54.4 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.1 years. The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2016 was $ 161.5 million and $ 37.0 million, respectively. The aggregate intrinsic value of the options exercised during the three months ended September 30, 2016 and 2015, was $ 8.8 million and $ 8.9 million, respectively. The following table summarizes option activity during the three months ended September 30, 2016:    Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,924,229 $ 38.70 3.2  Granted - -  Exercised (221,629) 28.44  Forfeited - -  Outstanding at end of period 1,702,600 $ 40.04 3.2  Exercise price of granted options $ -  Options exercisable at end of period 1,195,037 $ 33.81  The following table summarizes the activity of restricted stock units during the three months ended September 30, 2016:    Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,861,510 $ 50.52 1.4  Granted 7,539 63.68  Vested (10,279) 45.06  Forfeited (17,010) 50.69  Outstanding at end of period 1,841,760 $ 50.62 1.1  Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85 % of the fair market value of our common stock on the date of grant or 85 % of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $ 25,000 in common stock during any calendar year. At September 30, 2016, the number of shares remaining available for future issuance under the ESPP is 1.2 million shares.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements	(12) Fair Value Measurements  In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  The hierarchies of inputs are as follows:  · Level 1: Input prices quoted in an active market for identical financial assets or liabilities;  · Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and  · Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.  The following table summarizes our financial assets and liabilities, as at September 30, 2016 and June 30, 2016, using the valuation input hierarchy (in thousands):    Level 1 Level 2 Level 3 Total  Balances at September 30, 2016  Foreign currency hedging instruments, net $ - $ 612 $ - $ 612  Business acquisition contingent consideration $ - $ - $ (10,454) $ (10,454)  Balances at June 30, 2016  Foreign currency hedging instruments, net $ - $ 4,185 $ - $ 4,185  Business acquisition contingent consideration $ - $ - $ (10,450) $ (10,450)   We determine the fair value of our financial assets and liabilities as follows:  · Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.  · Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.  The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2016 and 2015 (in thousands):    Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ (10,450) $ (1,584)  Foreign currency translation adjustments (4) 70  Balance at the end of the period $ (10,454) $ (1,514)  We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2016 or June 30, 2016.

Legal Actions And Contingencies

Legal Actions And Contingencies	3 Months Ended
	Sep. 30, 2016
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(13) Legal Actions and Contingencies  Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.  Contingent Obligations Under Recourse Provisions  We use independent leasing companies to provide financing to certain customers for the purchase of our products. In some cases, and within certain limits, we are liable to the leasing companies in the event of a customer default for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold with recourse during the three months ended September 30, 2016 and 2015, amounted to $17.3 million and $16.1 million, respectively. The maximum potential amount s of contingent liability under these arrangements at September 30, 2016 and June 30, 2016 were $14.4 million, and $12.9 million, respectively. The recourse liability recognized by us at September 30, 2016 and June 30, 2016, in relation to these arrangements was $0.8 million and $0.7 million, respectively. 

Derivative Instruments And Hedg

Derivative Instruments And Hedging Activities	3 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities [Abstract]
Derivative Instruments And Hedging Activities	(14) Derivative Instruments and Hedging Activities  We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.  We held foreign currency instruments with notional amounts totaling $ 651.0 million and $ 612.2 million at September 30, 2016 and June 30, 2016, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to September 30, 2019.  The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2016 and June 30, 2016 (in thousands):    September 30, 2016 June 30, 2016 Balance Sheet Caption  Foreign currency hedging instruments $ 364 $ 2,346 Other assets - current  Foreign currency hedging instruments 2,504 2,082 Other assets - non current  Foreign currency hedging instruments (2,256) (243) Accrued expenses  Foreign currency hedging instruments - - Other long-term liabilities  $ 612 $ 4,185  The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2016 and 2015, respectively (in thousands):    Gain /(Loss) Recognized Income Statement Caption  Three Months Ended September 30,  2016 2015  Foreign currency hedging instruments $ 6,000 $ (39,353) Other, net  Other foreign-currency-denominated transactions (5,199) 37,081 Other, net  $ 801 $ (2,272)  We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Business Combinations

Business Combinations	3 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Business Combinations	(15) Business Combinations  Brightree  On April 4, 2016 we completed the acquisition of Brightree LLC (“Brightree”), a provider of cloud-based clinical and business management software for the post-acute care industry, for a total purchase consideration paid of $804 million. This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from April 4, 2016. The acquisition was funded through cash on-hand, funds available from our revolving credit facility and a new $300 million senior unsecured one-year term loan credit facility.  We have not completed the purchase price allocation in relation to this acquisition as certain appraisals associated with the valuation of intangible assets are not yet complete. We do not believe that the completion of this work will materially modify the preliminary purchase price allocation. We expect to complete our purchase price allocation during the quarter ending December 31, 2016. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. The preliminary fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands):     Brightree Intangible assets - useful life  Current assets $ 13,868  Property, plant and equipment 1,045  Tradenames 28,700 10 years  In-process research and development 4,100 n/a  Developed technology 114,700 5 to 6 years  Customer relationships 51,000 10 to 15 years  Goodwill 604,438  Assets acquired $ 817,851  Current liabilities (9,399)  Deferred revenue (4,571)  Deferred tax liabilities -  Total liabilities assumed $ (13,970)  Net assets acquired $ 803,881   Other Acquisitions  On October 2, 2015 we completed the acquisition of 100% of the shares in Curative Medical Technology Inc., a leading provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories in China. Curative Medical has its manufacturing base in Suzhou, China, offices in Beijing, Germany and the United States, and a distributor network throughout China and in other select markets.  On November 6, 2015 we completed the acquisition of 100% of the shares in Maribo Medico A/S, a distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders in Denmark and the Nordics.  On November 30, 2015 we completed the acquisition of 100% of the shares in Bennett Precision Tooling Pty Ltd, an Australian based company that designs and manufactures tools specializing in applications for Liquid Silicon Rubber.  On January 29, 2016 we completed the acquisition of 100% of the shares in Inova Labs Inc. (“Inova Labs”), a medical device company specializing in the development and commercialization of innovative oxygen therapy products.  These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from their respective acquisition dates. The acquisitions, individually and collectively, are not considered a material business combination and accordingly pro forma information is not provided. The acquisitions were funded through cash on-hand and by drawing on our existing credit facility.  Except for the purchase price allocation associated with the Inova Labs acquisition , we have completed the purchase price allocation in relation to all these acquisitions. We expect to complete our purchase price allocation for Inova Labs during the quarter ending December 31, 2016 . We do not believe that the completion of this work will materially modify the preliminary purchase price allocation for Inova Labs. The cost of the acquisitions was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is not deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.  The fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands):     All Other Intangible assets - useful life  Current assets $ 51,261  Property, plant and equipment 5,294  Tradenames 17,400 7 years  Non-compete 1,400 5 years  Developed technology 20,515 5 years  Customer relationships 37,303 5 to 8 years  Goodwill 192,325  Assets acquired $ 325,498  Current liabilities (21,147)  Debt assumed (21,201)  Deferred revenue (4,283)  Deferred tax liabilities (19,207)  Total liabilities assumed $ (65,838)  Net assets acquired $ 259,660 

Summary Of Significant Accoun22

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Sep. 30, 2016
Summary Of Significant Accounting Policies [Abstract]
Organization And Basis Of Presentation	Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2017.  The condensed consolidated financial statements for the three months ended September 30, 2016 and 2015 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2016.
New Accounting Pronouncements	New Accounting Pronouncements  In May, 2014, the FASB issued Accounting Standards Update (ASU), ASU No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact on our financial condition, results of operations and cash flows as a result of the adoption of ASU 2014-09, however, we do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard was effective for us beginning in the first quarter of fiscal 2017. As a result of the adoption, we reclassified debt issuance costs of $0.6 million and $1.7 million, from other assets to short-term debt and long-term debt, respectively, in our consolidated balance sheet as of June 30, 2016. The adoption of this guidance did not impact our consolidated statements of earnings, comprehensive income, s tock holders’ equity, or cash flows.  In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In February 2016, the FASB issued ASU No. 2016-02, “Leases”. Under the new guidance, lessees are required to recognize lease assets and liabilities on the balance sheet for leases classified as operating leases under current GAAP. This ASU is effective for the company beginning July 1, 2019. We are currently evaluating the impact of this standard on our consolidated financial statements.  In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting”, which requires companies to recognize additional tax benefits or expenses related to the vesting or settlement of employee share-based awards (the difference between the actual benefit for tax purposes and the tax benefit initially recognized for financial reporting purposes) as income tax benefit or expense in earnings, rather than in additional paid-in capital, in the reporting period in which they occur. This ASU also requires companies to classify cash flows resulting from employee share-based payments, including the additional tax benefits or expenses related to the vesting or settlement of share-based awards, as cash flows from operating activities rather than financing activities. The new standard is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. We elected to early adopt this ASU during the fourth quarter of fiscal year 2016 and are therefore required to report the impacts as though the ASU had been adopted on July 1, 2015. Accordingly, we recognized a reduction in income tax expense and an increase in operating cash flows related to the vesting or settlement of employee share-based awards of $2.5 million in each of the three month periods ended September 30, 201 6 and September 30, 201 5 .

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule Of Basic And Diluted Earnings Per Share	  Three Months Ended September 30,  2016 2015  Numerator:  Net Income $ 76,107 $ 82,917  Denominator:  Basic weighted-average common shares outstanding 140,785 140,309  Effect of dilutive securities:  Stock options and restricted stock units 1,305 1,971  Diluted weighted average shares 142,090 142,280  Basic earnings per share $ 0.54 $ 0.59  Diluted earnings per share $ 0.54 $ 0.58 

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Sep. 30, 2016
Inventories [Abstract]
Schedule Of Inventories	  September 30, 2016 June 30, 2016  Raw materials $ 65,416 $ 67,121  Work in progress 4,859 3,939  Finished goods 183,553 153,396  Total inventories $ 253,828 $ 224,456 

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	3 Months Ended
	Sep. 30, 2016
Property, Plant And Equipment [Abstract]
Components Of Property, Plant And Equipment	  September 30, 2016 June 30, 2016  Machinery and equipment $ 197,075 $ 197,485  Computer equipment 163,787 154,105  Furniture and fixtures 44,363 40,776  Vehicles 7,477 9,060  Clinical, demonstration and rental equipment 83,152 79,641  Leasehold improvements 34,126 33,795  Land 55,194 54,338  Buildings 233,047 229,502  818,221 798,702  Accumulated depreciation and amortization (427,424) (414,426)  Property, plant and equipment, net $ 390,797 $ 384,276 

Cost-Method Investments (Tables

Cost-Method Investments (Tables)	3 Months Ended
	Sep. 30, 2016
Cost-Method Investments [Abstract]
Schedule Of Reconciliation Of Changes In Cost-Method Investments	  Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ 33,815 $ 25,600  Investments 2,758 4,582  Balance at the end of the period $ 36,573 $ 30,182 

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Sep. 30, 2016
Goodwill And Other Intangible Asset [Abstract]
Schedule Of Changes In Carrying Amount Of Goodwill	  Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ 1,059,245 $ 264,261  Other adjustments, net 457 -  Foreign currency translation adjustments 3,056 (1,443)  Balance at the end of the period $ 1,062,758 $ 262,818 

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2016
Goodwill And Other Intangible Asset [Abstract]
Schedule Of Other Intangible Assets	  September 30, 2016 June 30, 2016  Developed/core product technology $ 203,041 $ 202,050  Accumulated amortization (72,493) (63,825)  Developed/core product technology, net 130,548 138,225  Trade names 48,624 47,897  Accumulated amortization (5,733) (3,832)  Trade names, net 42,891 44,065  Non-compete agreements 3,133 3,089  Accumulated amortization (2,013) (1,899)  Non compete agreements, net 1,120 1,190  Customer relationships 119,293 118,528  Accumulated amortization (29,905) (26,783)  Customer relationships, net 89,388 91,745  In-process research and development 4,100 4,100  Accumulated amortization - -  In-process research and development, net 4,100 4,100  Patents 78,388 74,034  Accumulated amortization (56,762) (53,551)  Patents, net 21,626 20,483  Total other intangibles, net $ 289,673 $ 299,808 

Product Warranties (Tables)

Product Warranties (Tables)	3 Months Ended
	Sep. 30, 2016
Product Warranties [Abstract]
Schedule Of Changes In Liability For Warranty Costs	  Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ 15,043 $ 9,823  Warranty accruals for the period 5,243 1,790  Warranty costs incurred for the period (2,855) (2,039)  Foreign currency translation adjustments 147 (691)  Balance at the end of the period $ 17,578 $ 8,883 

Debt (Tables)

Debt (Tables)	3 Months Ended
	Sep. 30, 2016
Debt [Abstract]
Schedule Of Debt	  September 30, 2016 June 30, 2016  Short-term debt $ 300,000 $ 300,000  Deferred borrowing costs (375) (562)  Short-term debt, net 299,625 299,438   Long-term debt 875,000 875,000  Deferred borrowing costs (1,489) (1,668)  Long-term debt, net 873,511 873,332  Total debt $ 1,173,136 $ 1,172,770 

Stock-Based Employee Compensa31

Stock-Based Employee Compensation (Tables)	3 Months Ended
	Sep. 30, 2016
Stock-Based Employee Compensation [Abstract]
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted	  Three Months Ended September 30,  2016 2015  Stock options:  Weighted average grant date fair value $ - $ -  Weighted average risk-free interest rate - -  Expected option life in years - -  Dividend yield - -  Expected volatility - -   ESPP purchase rights:  Weighted average grant date fair value $ 11.88 $ 14.22  Weighted average risk-free interest rate 0.4% 0.1%  Expected option life in years 6 months 6 months  Dividend yield 2.14% 1.73%  Expected volatility 23% 26% 

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2016
Stockholders' Equity [Abstract]
Schedule Of Option Activity	  Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,924,229 $ 38.70 3.2  Granted - -  Exercised (221,629) 28.44  Forfeited - -  Outstanding at end of period 1,702,600 $ 40.04 3.2  Exercise price of granted options $ -  Options exercisable at end of period 1,195,037 $ 33.81 
Schedule Of Activity Of Restricted Stock Units	  Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,861,510 $ 50.52 1.4  Granted 7,539 63.68  Vested (10,279) 45.06  Forfeited (17,010) 50.69  Outstanding at end of period 1,841,760 $ 50.62 1.1 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2016
Fair Value Measurements [Abstract]
Summary Of Financial Assets And Liabilities	  Level 1 Level 2 Level 3 Total  Balances at September 30, 2016  Foreign currency hedging instruments, net $ - $ 612 $ - $ 612  Business acquisition contingent consideration $ - $ - $ (10,454) $ (10,454)  Balances at June 30, 2016  Foreign currency hedging instruments, net $ - $ 4,185 $ - $ 4,185  Business acquisition contingent consideration $ - $ - $ (10,450) $ (10,450) 
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	  Three Months Ended September 30,  2016 2015  Balance at the beginning of the period $ (10,450) $ (1,584)  Foreign currency translation adjustments (4) 70  Balance at the end of the period $ (10,454) $ (1,514) 

Derivative Instruments And He34

Derivative Instruments And Hedging Activities (Tables)	3 Months Ended
	Sep. 30, 2016
Derivative Instruments And Hedging Activities [Abstract]
Summary Of Amount And Location Of Derivative Financial Instruments	  September 30, 2016 June 30, 2016 Balance Sheet Caption  Foreign currency hedging instruments $ 364 $ 2,346 Other assets - current  Foreign currency hedging instruments 2,504 2,082 Other assets - non current  Foreign currency hedging instruments (2,256) (243) Accrued expenses  Foreign currency hedging instruments - - Other long-term liabilities  $ 612 $ 4,185 
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	  Gain /(Loss) Recognized Income Statement Caption  Three Months Ended September 30,  2016 2015  Foreign currency hedging instruments $ 6,000 $ (39,353) Other, net  Other foreign-currency-denominated transactions (5,199) 37,081 Other, net  $ 801 $ (2,272) 

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Sep. 30, 2016
Brightree LLC [Member]
Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives	  Brightree Intangible assets - useful life  Current assets $ 13,868  Property, plant and equipment 1,045  Tradenames 28,700 10 years  In-process research and development 4,100 n/a  Developed technology 114,700 5 to 6 years  Customer relationships 51,000 10 to 15 years  Goodwill 604,438  Assets acquired $ 817,851  Current liabilities (9,399)  Deferred revenue (4,571)  Deferred tax liabilities -  Total liabilities assumed $ (13,970)  Net assets acquired $ 803,881 
All Other [Member]
Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives	  All Other Intangible assets - useful life  Current assets $ 51,261  Property, plant and equipment 5,294  Tradenames 17,400 7 years  Non-compete 1,400 5 years  Developed technology 20,515 5 years  Customer relationships 37,303 5 to 8 years  Goodwill 192,325  Assets acquired $ 325,498  Current liabilities (21,147)  Debt assumed (21,201)  Deferred revenue (4,283)  Deferred tax liabilities (19,207)  Total liabilities assumed $ (65,838)  Net assets acquired $ 259,660 

Summary Of Significant Accoun36

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs, short-term debt	$ 375		$ 562
Debt issuance costs, long-term debt	1,489		1,668
ASU 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs, short-term debt			600
Debt issuance costs, long-term debt			$ 1,700
ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Tax benefits	$ 2,500	$ 2,500

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Stock options and restricted stock units not included in the computation of diluted earnings per share	264,672	98,697

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Net income	$ 76,107	$ 82,917
Denominator:
Basic weighted-average common shares outstanding	140,785	140,309
Effect of dilutive securities:
Stock options and restricted stock units	1,305	1,971
Diluted weighted average shares	142,090	142,280
Basic earnings per share	$ 0.54	$ 0.59
Diluted earnings per share	$ 0.54	$ 0.58

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Inventories [Abstract]
Raw materials	$ 65,416	$ 67,121
Work in progress	4,859	3,939
Finished goods	183,553	153,396
Total inventories	$ 253,828	$ 224,456

Property, Plant And Equipment40

Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 818,221	$ 798,702
Accumulated depreciation and amortization	(427,424)	(414,426)
Property, plant and equipment, net	390,797	384,276
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	197,075	197,485
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	163,787	154,105
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	44,363	40,776
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,477	9,060
Clinical, Demonstration And Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	83,152	79,641
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	34,126	33,795
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	55,194	54,338
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 233,047	$ 229,502

Cost-Method Investments (Narrat

Cost-Method Investments (Narrative) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2015
Cost-Method Investments [Abstract]
Aggregate carrying amount of cost-method investments	$ 36,573	$ 33,815	$ 30,182	$ 25,600

Cost-Method Investments (Schedu

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cost-Method Investments [Abstract]
Balance at the beginning of the period	$ 33,815	$ 25,600
Investments	2,758	4,582
Balance at the end of the period	$ 36,573	$ 30,182

Goodwill (Schedule Of Changes I

Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Goodwill And Other Intangible Asset [Abstract]
Balance at the beginning of the period	$ 1,059,245	$ 264,261
Other adjustments, net	457
Foreign currency translation adjustments	3,056	(1,443)
Balance at the end of the period	$ 1,062,758	$ 262,818

Other Intangible Assets (Narrat

Other Intangible Assets (Narrative) (Details)	3 Months Ended
	Sep. 30, 2016
Minimum [Member]
Goodwill [Line Items]
Intangible assets, estimated useful life	2 years
Maximum [Member]
Goodwill [Line Items]
Intangible assets, estimated useful life	15 years

Other Intangible Assets (Schedu

Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Total other intangibles, net	$ 289,673	$ 299,808
Developed/Core Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	203,041	202,050
Accumulated amortization	(72,493)	(63,825)
Total other intangibles, net	130,548	138,225
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	48,624	47,897
Accumulated amortization	(5,733)	(3,832)
Total other intangibles, net	42,891	44,065
Non Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	3,133	3,089
Accumulated amortization	(2,013)	(1,899)
Total other intangibles, net	1,120	1,190
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	119,293	118,528
Accumulated amortization	(29,905)	(26,783)
Total other intangibles, net	89,388	91,745
In-Process Research And Development [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	4,100	4,100
Total other intangibles, net	4,100	4,100
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	78,388	74,034
Accumulated amortization	(56,762)	(53,551)
Total other intangibles, net	$ 21,626	$ 20,483

Product Warranties (Schedule Of

Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Product Warranties [Abstract]
Balance at the beginning of the period	$ 15,043	$ 9,823
Warranty accruals for the period	5,243	1,790
Warranty costs incurred for the period	(2,855)	(2,039)
Foreign currency translation adjustments	147	(691)
Balance at the end of the period	$ 17,578	$ 8,883

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Thousands	Apr. 04, 2016	Sep. 30, 2016	Jun. 30, 2016	Apr. 03, 2016	Oct. 31, 2013
Debt Instrument [Line Items]
Outstanding under the revolving credit facility		$ 875,000	$ 875,000
Outstanding under the term loan credit agreement		$ 300,000	$ 300,000
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 700,000
Credit facility termination date		Oct. 31, 2018
Interest rate on outstanding principal amount		2.00%
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 25,000
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.15%
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		1.00%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.25%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		2.00%
Brightree LLC [Member] | Term Loan Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 300,000
Credit facility term, years	1 year
Credit facility termination date		Apr. 3, 2017
Interest rate on outstanding principal amount		2.00%
Brightree LLC [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000
Uncommitted option to increase credit facility	$ 300,000
Brightree LLC [Member] | Minimum [Member] | Term Loan Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		1.00%
Brightree LLC [Member] | Maximum [Member] | Term Loan Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		2.00%

Debt (Schedule Of Debt) (Detail

Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Debt [Abstract]
Short-term debt	$ 300,000	$ 300,000
Deferred borrowing costs	(375)	(562)
Short-term debt, net	299,625	299,438
Long-term debt	875,000	875,000
Deferred borrowing costs	(1,489)	(1,668)
Long-term debt, net	873,511	873,332
Total debt	$ 1,173,136	$ 1,172,770

Stock-Based Employee Compensa49

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) - $ / shares	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value
Weighted average risk-free interest rate
Dividend yield
Expected volatility
ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 11.88	$ 14.22
Weighted average risk-free interest rate	0.40%	0.10%
Expected option life in years	6 months	6 months
Dividend yield	2.14%	1.73%
Expected volatility	23.00%	26.00%

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares	Sep. 30, 2015USD ($)	Jun. 30, 2016USD ($)$ / sharesshares	Apr. 30, 1997$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares repurchased pursuant to the repurchase program	41,086,234		41,086,234
Total cost of shares repurchased pursuant to the repurchase program | $	$ 1,546,611		$ 1,546,611
Common shares repurchased	0
Additional shares that can be repurchased under the approved share repurchase program	13,600,000
Preferred stock, shares authorized	2,000,000		2,000,000
Preferred stock at par value | $ / shares	$ 0.01		$ 0.01
Preferred stock, shares issued	0		0
Unrecognized compensation costs related to unvested stock-based compensation arrangements | $	$ 54,400
Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements	2 years 1 month 6 days
Aggregate intrinsic value of the stock-based compensation arrangements outstanding | $	$ 161,500
Aggregate intrinsic value of the stock-based compensation arrangements exercisable | $	37,000
Aggregate intrinsic value of the options exercised | $	$ 8,800	$ 8,900
Series A Junior Participating Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized				2,000,000
Preferred stock at par value | $ / shares				$ 0.01
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option expiration period	7 years
Common stock authorized for issuance	43,700,000
Reduction in the number of shares of common stock available for issuance	2.8
Number of securities remaining available for future issuance	12,100,000
Maximum number of shares subject to awards granted	3,000,000
Number of common stock shares granted in participant's initial year of hiring	4,500,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities remaining available for future issuance	1,200,000
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant	85.00%
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase	85.00%
Minimum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period	1 year
Minimum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period	3 months
Maximum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period	4 years
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period	27 months
Common stock shares subscribed | $	$ 25

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period	1,924,229
Options, Granted
Options, Exercised	(221,629)
Options, Forfeited
Options, Outstanding at end of period	1,702,600	1,924,229
Options, Exercise price of granted options
Options exercisable at end of period	1,195,037
Weighted Average Exercise Price, Outstanding at beginning of period	$ 38.70
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised	28.44
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding at end of period	40.04	$ 38.70
Weighted Average Exercise Price, Options exercisable at end of period	$ 33.81
Weighted Average Remaining Contractual Term in Years, Outstanding	3 years 2 months 12 days	3 years 2 months 12 days

Stockholders' Equity (Schedul52

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	1,861,510
Restricted Stock Units, Granted	7,539
Restricted Stock Units, Vested	(10,279)
Restricted Stock Units, Forfeited	(17,010)
Restricted Stock Units, Outstanding at end of period	1,841,760	1,861,510
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$ 50.52
Weighted Average Grant-Date Fair Value, Granted	63.68
Weighted Average Grant-Date Fair Value, Vested	45.06
Weighted Average Grant-Date Fair Value, Forfeited	50.69
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$ 50.62	$ 50.52
Weighted Average Remaining Contractual Term in Years, Outstanding	1 year 1 month 6 days	1 year 4 months 24 days

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 612	$ 4,185
Business acquisition contingent consideration	(10,454)	(10,450)
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	612	4,185
Business acquisition contingent consideration
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration	$ (10,454)	$ (10,450)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value Measurements [Abstract]
Balance at the beginning of the period	$ (10,450)	$ (1,584)
Foreign currency translation adjustments	(4)	70
Balance at the end of the period	$ (10,454)	$ (1,514)

Legal Actions And Contingenci55

Legal Actions And Contingencies (Narrative) (Details) - Contingent Obligations Under Recourse Provisions [Member] - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Loss Contingencies [Line Items]
Receivables sold to leasing companies under debt factoring arrangements	$ 17.3	$ 16.1
Maximum potential contingent liability	14.4		$ 12.9
Recourse liability recognized	$ 0.8		$ 0.7

Derivative Instruments And He56

Derivative Instruments And Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Derivative [Line Items]
Notional amount of foreign currency hedging contracts held	$ 651	$ 612.2
Foreign Currency Hedging Instruments [Member]
Derivative [Line Items]
Terms of foreign currency hedging contracts, maximum	3 years

Derivative Instruments And He57

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) - Foreign Currency Hedging Instruments [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Jun. 30, 2016
Derivatives, Fair Value [Line Items]
Net foreign currency hedging instruments	$ 612	$ 4,185
Other Assets - Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	364	2,346
Other Assets - Non Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	2,504	2,082
Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	$ (2,256)	$ (243)

Derivative Instruments And He58

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) - Derivatives Not Designated As Hedging Instruments [Member] - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income	$ 801	$ (2,272)
Foreign Currency Hedging Instruments [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency hedging instruments	6,000	(39,353)
Other Foreign-Currency-Denominated Transactions [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other foreign-currency-denominated transactions	$ (5,199)	$ 37,081

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) - USD ($) $ in Millions	Apr. 04, 2016	Sep. 30, 2016
Brightree LLC [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Apr. 4, 2016
Total purchase price of acquisition	$ 804
Brightree LLC [Member] | Term Loan Credit Agreement [Member]
Business Combinations [Line Items]
Maximum borrowing capacity	$ 300
Credit facility term, years	1 year
Curative Medical Technology Inc [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Oct. 2, 2015
Percentage of outstanding shares acquired		100.00%
Maribo Medico A/S [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Nov. 6, 2015
Percentage of outstanding shares acquired		100.00%
Bennett Precision Tooling Pty Ltd [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Nov. 30, 2015
Percentage of outstanding shares acquired		100.00%
Inova Labs [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Jan. 29, 2016
Percentage of outstanding shares acquired		100.00%

Business Combinations (Schedule

Business Combinations (Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016
Business Combinations [Line Items]
Goodwill	$ 457
Brightree LLC [Member]
Business Combinations [Line Items]
Current assets		$ 13,868
Property, plant and equipment		1,045
Goodwill		604,438
Assets acquired		817,851
Current liabilities		(9,399)
Deferred revenue		(4,571)
Total liabilities assumed		(13,970)
Net assets acquired		803,881
All Other [Member]
Business Combinations [Line Items]
Current assets		51,261
Property, plant and equipment		5,294
Goodwill		192,325
Assets acquired		325,498
Current liabilities		(21,147)
Debt assumed		(21,201)
Deferred revenue		(4,283)
Deferred tax liabilities		(19,207)
Total liabilities assumed		(65,838)
Net assets acquired		259,660
Trade Names [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 28,700
Intangible assets, useful life		10 years
Trade Names [Member] | All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 17,400
Intangible assets, useful life		7 years
In-Process Research And Development [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 4,100
Non-Compete [Member] | All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 1,400
Intangible assets, useful life		5 years
Developed Technology [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 114,700
Developed Technology [Member] | All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 20,515
Intangible assets, useful life		5 years
Developed Technology [Member] | Minimum [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		5 years
Developed Technology [Member] | Maximum [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		6 years
Customer Relationships [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets		$ 51,000
Customer Relationships [Member] | All Other [Member]
Business Combinations [Line Items]
Intangible assets		$ 37,303
Customer Relationships [Member] | Minimum [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		10 years
Customer Relationships [Member] | Minimum [Member] | All Other [Member]
Business Combinations [Line Items]
Intangible assets, useful life		5 years
Customer Relationships [Member] | Maximum [Member] | Brightree LLC [Member]
Business Combinations [Line Items]
Intangible assets, useful life		15 years
Customer Relationships [Member] | Maximum [Member] | All Other [Member]
Business Combinations [Line Items]
Intangible assets, useful life		8 years